RF
RFL.US Rafael Holdings, Inc.
- Market cap
- USD 47.7M
- P/E
- -
- P/B
- 0.76x
- ROE
- -44.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jul 2026.
Is RFL.US undervalued?
Graham numberThe Graham number of Rafael Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rafael Holdings, Inc. fundamental analysis
No fundamental analysis for Rafael Holdings, Inc. yet.
Rafael Holdings, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C (NPC), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog o…
Full company profileRafael Holdings, Inc. financial statements
Rafael Holdings, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 5.62M | 4.37M | 4.93M | 4.91M | 802K | 410K | 279K | 637K | 917K | 874K |
| Gross Profit | 5.62M | 4.37M | 4.93M | 4.91M | 802K | 410K | 279K | 483K | 495K | 628K |
| Operating Income | 221K | -3.84M | -6.70M | -8.47M | -21.2M | -60.5M | -15.0M | -103M | -26.1M | -33.4M |
| EBITDA | 1.89M | -1.94M | -3.16M | -5.02M | -23.3M | -140M | -8.67M | -66.8M | -32.3M | -33.2M |
| Net Income | 138K | -11.6M | -4.92M | -10.4M | -24.5M | -125M | -1.88M | -34.4M | -30.5M | -29.6M |
| EPS | 0.01 | -0.93 | -0.37 | -0.66 | -1.49 | -6.31 | -0.08 | -1.45 | -1.04 | -0.58 |
| Balance Sheet | ||||||||||
| Total Assets | 86.2M | 117M | 142M | 136M | 154M | 118M | 98.8M | 96.8M | 114M | 83.1M |
| Total Liabilities | 24.1M | 1.36M | 17.4M | 5.82M | 17.4M | 21.1M | 2.20M | 10.6M | 15.7M | 11.1M |
| Shareholders' Equity | 52.7M | 107M | 111M | 131M | 122M | 101M | 100M | 82.2M | 94.4M | 66.3M |
| Cash & Short-term Investments | 11.8M | 40.5M | 12.0M | 6.21M | 7.85M | 63.2M | 79.5M | 65.9M | 52.8M | 22.1M |
| Total Debt | - | - | 14.9M | 1.19M | 14.5M | 15.0M | - | 2.39M | 692K | 610K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.62M | -1.82M | -3.13M | -4.67M | -15.6M | -26.1M | -10.9M | -7.80M | -18.9M | -30.0M |
| Capital Expenditure | 1.82M | 710K | 399K | 534K | 206K | 2.00K | 51.7M | 178K | 4.00K | 5.00K |
| Free Cash Flow | -3.44M | -2.53M | -3.53M | -5.20M | -15.8M | -26.1M | 40.8M | -7.98M | -18.9M | 14.3M |
| Ratios | ||||||||||
| ROE | 0.3% | -10.9% | -4.4% | -8.0% | -20.1% | -124.0% | -1.9% | -41.9% | -32.3% | -44.7% |
| ROA | 0.2% | -10.0% | -3.5% | -7.6% | -15.9% | -105.4% | -1.9% | -35.5% | -26.7% | -35.7% |
| Net Profit Margin | 2.5% | -266.5% | -99.9% | -212.1% | -3,060.3% | -30,404.4% | -672.4% | -5,401.9% | -3,328.2% | -3,390.7% |
| Debt to Equity | - | - | 0.13x | 0.01x | 0.12x | 0.15x | - | 0.03x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rafael Holdings, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 18.3M | 1.38 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1014:1000 on May 9, 2025.
Who owns Rafael Holdings, Inc.
- Insiders 38.08%
- Institutions 8.38%
- Public & others 53.55%
- Shares outstanding 51.4M
- Free float 31.9M
Top funds holding RFL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 976K | 1.87% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 170K | 0.33% | -14.50% | Sep 2026 |
| iShares Micro-Cap ETF | 100K | 0.19% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 92.7K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 74.9K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 58.5K | 0.11% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 27.7K | 0.05% | 0.00% | Oct 2026 |
| DFA U.S. Vector Equity I | 24.0K | 0.05% | +16.59% | Sep 2026 |
| DFA U.S. Core Equity 2 Instl | 20.2K | 0.04% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 19.7K | 0.04% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 18.7K | 0.04% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 18.0K | 0.03% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 17.0K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 16.2K | 0.03% | 0.00% | Oct 2026 |
| Gestión Boutique VII Azagala FI | 11.9K | 0.02% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 9.44K | 0.02% | -14.09% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 7.76K | 0.01% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 7.21K | 0.01% | 0.00% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 5.11K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding RFL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.37M | 2.62% | +8.42% | Jun 2026 |
| Geode Capital Management, LLC | 430K | 0.82% | -2.83% | Jun 2026 |
| BlackRock Inc | 390K | 0.75% | +6.69% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 289K | 0.55% | +3.54% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 207K | 0.40% | +0.76% | Jun 2026 |
| IEQ CAPITAL, LLC | 165K | 0.32% | -13.16% | Jun 2026 |
| State Street Corp | 157K | 0.30% | +152.97% | Jun 2026 |
| Kahn Brothers & CO Inc /DE/ | 150K | 0.29% | +157.00% | Jun 2026 |
| Jane Street Group LLC | 113K | 0.22% | +150.24% | Jun 2026 |
| Wells Fargo & Co | 104K | 0.20% | +0.23% | Jun 2026 |
| Renaissance Technologies Corp | 103K | 0.20% | +71.37% | Sep 2026 |
| Northern Trust Corp | 88.6K | 0.17% | +5.46% | Jun 2026 |
| Susquehanna International Group, LLP | 70.7K | 0.14% | +203.60% | Jun 2026 |
| LPL Financial Corp | 55.8K | 0.11% | -1.15% | Jun 2026 |
| Citadel Advisors Llc | 49.1K | 0.09% | +364.25% | Jun 2026 |
| HPM Partners LLC | 44.0K | 0.08% | -1.59% | Jun 2026 |
| Americana Partners, LLC | 43.8K | 0.08% | 0.00% | Sep 2026 |
| Wellington Shields Capital Mgmt LLC | 29.0K | 0.06% | +11.36% | Jun 2026 |
| Wealth Enhancement Advisory Services, LLC | 16.9K | 0.03% | -8.94% | Jun 2026 |
| Virtu Financial LLC | 14.2K | 0.03% | +4.26% | Jun 2026 |
Rafael Holdings, Inc. company profile
- Company name
- Rafael Holdings, Inc.
- Ticker
- RFL.US
- Exchange
- USA Stocks
- Listed since
- Mar 26, 2018
- Sector
- Real Estate
- Industry
- Real Estate Management & Development
- Employees
- 15
- Fiscal year end
- July
- Address
- 520 Broad Street, Newark, NJ, United States, 07102
- Phone
- 212 658 1450
- Website
- rafaelholdings.com
About Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C (NPC), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate. The company is also involved in developing Promitil, a pegylated liposomal mitomycin-C lipidic prodrug which is designed molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form. In addition, it develops surgical and procedural devices, including orthopedic arthroscopy instrument for carpal and cubital tunnel syndrome. Further, the company provides technological solutions specifically engineered for increased bioavailability of cannabinoids. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Rafael Holdings, Inc. management
4- Mr. Howard S. JonasCEO, President, Founder & Executive Chairman · born 1956
- Mr. David A. Polinsky Esq.Chief Financial Officer · born 1972
- Mr. Joshua M. FineChief Operating Officer · born 1982
- Ms. Joyce J. Mason Esq.Corporate Secretary · born 1959